Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.
MRI
PSMA PET
SBRT
prostate cancer
stereotactic
ultrahypofractionated
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
01
2022
accepted:
07
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Advances in imaging have changed prostate radiotherapy through improved biochemical control from focal boost and improved detection of recurrence. These advances are reviewed in the context of prostate stereotactic body radiation therapy (SBRT) and the ARGOS/CLIMBER trial protocol. ARGOS/CLIMBER will evaluate 1) the safety and feasibility of SBRT with focal boost guided by multiparametric MRI (mpMRI) and
Identifiants
pubmed: 35494042
doi: 10.3389/fonc.2022.863848
pmc: PMC9043802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
863848Informations de copyright
Copyright © 2022 Liu, Loblaw, Laidley, Fakir, Mendez, Davidson, Kassam, Lee, Ward, Thiessen, Bayani, Conyngham, Bailey, Andrews and Bauman.
Déclaration de conflit d'intérêts
T-YL declares receiving royalties from GE Healthcare. JB declares receiving grants from Thermo Fisher Scientific and payments or honoraria from Thermo Fisher Scientific and NanoString Technologies, Inc., and has two pending patents. GB declares grants from the Ontario Institute for Cancer Research, Ontario Health, and Centre for Probe Development and Commercialization and industry collaboration with Siemens Healthineers and InVicro. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Sci Rep. 2020 Sep 7;10(1):14713
pubmed: 32895442
Eur Urol Focus. 2018 Sep;4(5):702-706
pubmed: 28753797
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):423-430
pubmed: 32999466
Radiother Oncol. 2021 Jun;159:33-38
pubmed: 33587971
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Cancers (Basel). 2021 Nov 18;13(22):
pubmed: 34830950
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):501-508
pubmed: 32808077
J Clin Oncol. 2021 Mar 1;39(7):787-796
pubmed: 33471548
Radiother Oncol. 2020 Jun;147:92-98
pubmed: 32247206
Radiother Oncol. 2020 Nov;152:34-41
pubmed: 32827589
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):371-8
pubmed: 20421147
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):188-96
pubmed: 27375167
EJNMMI Res. 2021 Oct 15;11(1):107
pubmed: 34652551
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):546-555
pubmed: 31730876
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):715-724
pubmed: 31812718
J Nucl Med. 2017 Nov;58(11):1805-1810
pubmed: 28473595
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):136-142
pubmed: 31987962
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Cancer. 2009 Feb 1;115(3):673-9
pubmed: 19117039
Front Oncol. 2020 Dec 07;10:600690
pubmed: 33365271
J Nucl Med. 2020 May;61(5):729-734
pubmed: 31628219
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e441-8
pubmed: 22284038
J Nucl Med. 2018 Jul;59(7):1076-1080
pubmed: 29269569
Clin Transl Radiat Oncol. 2021 Nov 14;32:41-47
pubmed: 34841094
J Nucl Med. 2019 Jul;60(7):944-949
pubmed: 30552201
Radiother Oncol. 2022 Jan;166:1-7
pubmed: 34774650
Eur Urol Oncol. 2021 Dec;4(6):868-876
pubmed: 33582104
Radiother Oncol. 2020 Oct;151:26-32
pubmed: 32663537
Expert Rev Anticancer Ther. 2021 Jun;21(6):641-655
pubmed: 33476253
Adv Radiat Oncol. 2020 Sep 09;6(1):100553
pubmed: 33521396
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Adv Radiat Oncol. 2019 Sep 27;5(2):212-220
pubmed: 32280821
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1047-55
pubmed: 15519774
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8
pubmed: 18495377
Adv Radiat Oncol. 2020 May 12;5(5):965-977
pubmed: 33083660
Eur Urol. 2021 Dec;80(6):682-689
pubmed: 34465492
Eur Urol Oncol. 2021 Oct;4(5):821-825
pubmed: 32088155
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
Eur Urol. 2021 Dec 22;:
pubmed: 34953603
J Clin Oncol. 2022 May 1;40(13):1500-1505
pubmed: 35015566
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):719-24
pubmed: 22436789
Radiother Oncol. 2018 Apr;127(1):74-80
pubmed: 29336835
Eur Urol. 2021 Sep;80(3):280-292
pubmed: 33309278
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13
pubmed: 21605949
J Nucl Med. 2020 Apr;61(4):546-551
pubmed: 31628216
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366
Can Urol Assoc J. 2021 Nov;15(11):E620-E621
pubmed: 33999811
Pract Radiat Oncol. 2022 May-Jun;12(3):e201-e206
pubmed: 34619375
Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1115-1122
pubmed: 34740768
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476
pubmed: 32617640
AJR Am J Roentgenol. 2020 Sep;215(3):652-659
pubmed: 32755168
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):42-49
pubmed: 30611838
J Clin Oncol. 2020 Jun 10;38(17):1963-1996
pubmed: 31940221
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2978-2989
pubmed: 33550425